secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001213900-24-056807
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed amends ATM equity offering agreement with H.C. Wainwright
---------------------------------------------------------------

- Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.
- Settlement cycle updated to T+1 (first trading day) to reflect current market rules.
- New data privacy compliance representation added; $50k cap on agent's counsel fees reimbursed.
- Company to file a prospectus supplement and deliver customary closing deliverables on June 27, 2024.
- Prior letter agreements from October 2023 and June 2024 remain effective unless conflicting with amended ATM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/0001213900-24-056807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/ea0208584-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-056807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer